SOLV Stock Chart & Stats
$1382.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1382.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,080.01 - $1,572.99
Previous CloseN/A
Volume0.00
Average Volume (3M)12.00
Market Cap
$256.68B
Enterprise ValueN/A
Total Cash (Recent Filing)$561.00M
Total Debt (Recent Filing)$5.08B
Price to Earnings (P/E)10.4
Beta-0.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.21
Shares Outstanding173,174,710
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.73
Price to Sales (P/S)1.66
P/FCF Ratio-1.38K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,472.92Price Target Upside6.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Margin StrengthSustained high gross margins (56.4%) and near-20% operating margin reflect durable pricing power and cost structure advantages in medical consumables and services. Management is targeting further operating margin expansion to 21.0%–21.5%, which supports long-term cash generation and reinvestment capacity even if revenue growth is uneven.
Diversified Segment GrowthMultiple business lines showing organic growth reduces revenue concentration risk: MedSurg, Dental, and Health Information Systems all grew organically. This portfolio mix (consumables, devices, and software/analytics) provides structural stability and multiple levers for sustainable revenue and margin recovery over the medium term.
$500M Transform Savings ProgramA formal $500M Transform for the Future program signals a structural cost-reduction roadmap through automation, footprint optimization and SKU rationalization. Realizing these savings will lower the company's operating breakeven, improve margins and enhance free cash flow resilience across planning horizons beyond transient headwinds.
Bears Say
Weak Cash GenerationThe persistent gap between reported earnings and actual operating cash flow is a fundamental risk: negative free cash flow constrains debt reduction, capex and shareholder returns. If structural drivers of cash weakness persist, the company may need to slow buybacks or redirect savings to preserve liquidity, limiting financial flexibility.
Elevated Net DebtNet debt near $4.5B leaves leverage sensitive to weak cash conversion and cyclical revenue. Management continues buybacks and M&A activity while prioritizing leverage reduction, but elevated debt increases refinancing, interest and covenant risk and reduces headroom to absorb operational or separation-related shocks over the medium term.
Revenue VolatilityFlat annual revenue and a sharp TTM decline create structural uncertainty about demand and comparability. While some drag stems from portfolio moves, SKU rationalization and ERP timing, persistent or recurring revenue weakness would pressure margins and cash flow, making medium-term targets harder to sustain without renewed organic growth.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $1080.01 and its highest was $1572.99 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $256.68B.
When is Solventum Corporation’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on May 05, 2026. The company reported $25.767 earnings per share for the quarter, beating the consensus estimate of $23.556 by $2.211.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 173,174,710 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $25.767 in its last earnings report, beating expectations of $23.556. Following the earnings report the stock price went up 2.709%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in MX:SOLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solventum Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,472.92 (6.58% Upside)
$1,472.92 (6.58% Upside)
Blogger Sentiment
Bullish
MX:SOLV Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
SOLV Company Deck
SOLV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: Q1 results beat expectations with organic growth, EPS upside (+11% YoY), improved gross margins (+80 bps), strong segment performance (MedSurg, Dental, HIS) and tangible progress on separation, SKU rationalization, and integration of Acera. Management reiterated multiyear savings (Transform for the Future $500M) and an intent to accelerate share repurchases while maintaining full-year guidance. The primary negatives are timing and separation-related volatility: reported sales declined -3% due to acquisition/divestiture impacts, tariff and inflationary headwinds ($100M–$120M range) remain, ERP cutover phasing will drive >$100M of order timing into Q2 that reverses in Q3, and certain legacy product lines (clinician productivity solutions) face double-digit declines. Overall, most issues are described as transitory or manageable via mitigation programs and the company emphasized accelerating margin expansion and product-driven growth, supporting a constructive outlook.View all MX:SOLV earnings summariesSOLV Stock 12 Month Forecast
Average Price Target
$1,472.92
▲(6.58% Upside)